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Abstract 
Aim. Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until now technological 
limitations have hindered elucidation of the contribution of all clinically relevant disease genes to DCM 
phenotypes in larger cohorts. We now utilized next-generation sequencing to overcome these limitations and 
screened all DCM disease genes in a large cohort. 
Methods and results. In this multi-centre, multi-national study, we have enrolled 639 patients with sporadic or 
familial DCM. To all samples, we applied a standardized protocol for ultra-high coverage next-generation 
sequencing of 84 genes, leading to 99.1% coverage of the target region with at least 50-fold and a mean read 
depth of 2415. In this well characterized cohort, we find the highest number of known cardiomyopathy 
mutations in plakophilin-2, myosin-binding protein C-3, and desmoplakin. When we include yet unknown but 
predicted disease variants, we find titin, plakophilin-2, myosin-binding protein-C 3, desmoplakin, ryanodine 
receptor 2, desmocollin-2, desmoglein-2, and SCN5A variants among the most commonly mutated genes. 
The overlap between DCM, hypertrophic cardiomyopathy (HCM), and channelopathy causing mutations is 
considerably high. Of note, we find that >38% of patients have compound or combined mutations and 12.8% 
have three or even more mutations. When comparing patients recruited in the eight participating European 
countries we find remarkably little differences in mutation frequencies and affected genes. 
Conclusion. This is to our knowledge, the first study that comprehensively investigated the genetics of DCM 
in a large-scale cohort and across a broad gene panel of the known DCM genes. Our results underline the 
high analytical quality and feasibility of Next-Generation Sequencing in clinical genetic diagnostics and 
provide a sound database of the genetic causes of DCM. 
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Introduction 
Dilated cardiomyopathy (DCM) accounts for 30–40% of all heart failure cases in large clinical 
trials and is the leading cause of heart transplantation. There is ample data on the familial 
aggregation of DCM and in recent registers familial forms of DCM account for 30–50% of all 
DCM cases. With an autosomal-dominant inheritance being the predominant pattern of 
transmission, some familial cases also present by an autosomal recessive or X-linked recessive 
trait. Particularly in western countries, the small size of contemporary families may obscure the 
genetic nature of the disease and it is important to consider that also sporadic DCM cases can be 
due to genetic mutations.
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Tremendous advances have been made in understanding the genetic basis of DCM. Linkage 
analyses in families and candidate gene sequencing as well as genome-wide association studies 
(GWAS) in large cohorts
2
 have contributed to the identification of risk variants and disease 
causing mutations in >30 disease genes, many of which encode for structural components of the 
heart muscle, such as the sarcomere or the cardiac z-disc. Recently, we and others have used Next-
Generation Sequencing (NGS) approaches to dissect the genetic causes of DCM and established a 
comprehensive methodology for the clinical genetic testing of all currently known disease genes.
3
 
However, the existing studies are either limited by the small number of investigated patients or the 
restriction to only a subset of disease genes, prohibiting a more detailed dissection of the role of 
DNA-alterations in DCM. 
 
We are here presenting the results of the gene sequencing study of the European 
INHERITANCE project including 639 patients with sporadic or proven familial DCM enrolled in 
eight different clinical centres (Denmark, Sweden, France, Italy, Germany, UK, Netherlands, and 
Spain). We aimed to systematically investigate not only the clinically relevant DCM genes but 
also genes causative for other inherited cardiomyopathies and to systematically benchmark the 
analytical performance of NGS as a novel technology being introduced into broad clinical 
application. 
Methods 
Patients and study design 
This multi-centre study was conducted in accordance with the principles of the Declaration of 
Helsinki. All participants from all centres have given written informed consent and the study was 
approved by the ethic committees of the participating study centres. 
 
Dilated cardiomyopathy was diagnosed according to the WHO/International Society and 
Federation of Cardiology Task Force clinical criteria,
4
 defined as a myocardial disorder 
characterized by the presence of left ventricular dilatation and systolic impairment, in the absence 
of abnormal loading conditions (e.g. hypertension, valve disease) or coronary artery disease 
(CAD) sufficient to cause global systolic dysfunction.
5
 Specific criteria were the presence of left 
ventricular dilatation (>117% of the predicted value corrected for age and body surface area using 
the Henry equation) and left ventricular systolic dysfunction (LVEF <45%) in the absence of 
abnormal loading conditions (e.g. hypertensive heart disease, primary valve disease) or CAD with 
stenosis >50% of at least one main vessel in coronary angiography. CAD was ruled out by 
coronary angiography in 53% of patients (n = 338). Patients having clinic suspicion or evidence 
for myocarditis [late-Gadolinium enhancement typical for myocarditis in cardiac MRI (69 patients 
(11%) of all patients undergone MRI), or evidence from myocardial biopsies (121 patients (19%) 
of all patients undergone biopsy)] or history of cardio-toxic therapies were excluded. Familial 
DCM was defined according to ESC definitions
5
 and evaluated according to the position statement 
of the European Society of Cardiology, Working Group on Myocardial and Pericardial Diseases.
6
 
In detail, all familial DCM cases had at least one additional affected family member with DCM or 
one case of sudden cardiac death earlier 35 years of age in the pedigree. All criteria had to be met 
at an initial diagnosis of DCM in probands or relatives. Clinical data for association analysis were 
assessed during the index visit, where it was required that the patient was clinically stable for at 
least 4 weeks. The enrolment was at the index visit of patients between 2009 and 2011, NGS was 
performed between March 2011 and August 2013 after DNA was extracted at the recruiting centre 
and shipped pseudonymized to the INHERITANCE sequencing core centre (Department of 
Cardiology, University of Heidelberg, Germany). 
Target enrichment, next-generation sequencing, and data analysis 
SureSelect
XT
 Target Enrichment System (Agilent; Waldbronn, Germany) was used for 
capturing of the desired regions. Design of the capture baits was done using eArray (Agilent 
Technologies, Santa Clara, CA, USA). Raw data analysis was performed with an in-house pipeline 
based on variant calling of the Genome Analysis Toolkit (GATK). Annotation of the variants was 
mainly done using ANNOVAR. Genotype–phenotype association tests were done with the SAS 
software. For a detailed description of the data analysis, please refer to the Supplemental Material 
online. 
Variant classification 
In this study, we relied on distinct, well-defined categories for the classification of variants. 
Variants were classified as benign when present in ‘dbSNP137common’ 
(http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/snp137Common.sql) and flagged as 
validated-by-frequency, which means that those variants have been found with an allele-frequency 
of ≥1% in populations. For further determination of the likelihood to being disease relevant 
mutations, we defined distinct categories (see also Figure 1C): category Ia consists of coding 
human genome mutation database (HGMD) disease mutations (heart muscle diseases and 
channelopathies) and either are non-synonymous, frameshift insertions or deletions, splice or 
start/stop mutations. The same definition was applied for category Ib, where we additionally 
removed variants present in the 4300 individuals of the European-Americans cohort of the NHLBI 
GO Exome Sequencing Project (ESP) database (http://evs.gs.washington.edu/EVS/). As category 
II, we defined all not common, truncating variants that are either frameshift insertions/deletions, 
splice, or start/stop variants. Finally, all not common non-synonymous variants with prediction 
‘disease’ were classified as category III. The predictions were based on SNPs&GO 
(February/March 2013; http://snps.biofold.org/snps-and-go//snps-and-go.html).
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Figure 1. Study design. (A) The map is showing the participating European countries and the number of patients included 
(absolute and in brackets relative). Map (EU27-European_Union_map.svg) by Kolja21, used under CC BY. (B) Applied 
workflow, consisting of target-enrichment of cardiomyopathy related genes, next-generation sequencing and data analysis. 
(C) Overview of variant classification. Total number of patients in the whole cohort is given in brackets. 
Genotype–phenotype association analysis 
Association analyses were carried out using the SAS software version 9.2 (SAS Institute, Inc., 
Cary, NC, USA). Patients were characterized by gender, country, family history of DCM, LVEF, 
LVEDD, NYHA classification, age at diagnosis, heart transplantation, and implantation of ICD 
according to available information. Based on the above-described variant classification, the 
number of variants, the number of patients carrying at least one variant, the number of patients 
carrying at least two variants in a single investigated gene, and the number of patients carrying at 
least two variants in any investigated gene were calculated for each group. Probability values and 
effect sizes with 95% confidence intervals were estimated based on logistic and Poisson regression 
assuming a dominant penetrance model. To identify the most relevant DCM variants according to 
their function, a stepwise forward model selection was carried out. The list of explanatory 
variables included the variant carrier status in genes grouped by function (ion flux, nucleus, cell 
membrane, sarcomeric, cystoskeleton, and intercalated disc). Significant explanatory variables at 
the 5% level (score test) entered the models and they were not removed if they remained 
significant at the 10% level. Because of the exploratory nature of the genotype–phenotype 
association analysis, no correction for multiple testing has been applied. 
  
Results 
Ultra-high coverage next-generation sequencing enables comprehensive diagnostics of dilated 
cardiomyopathy 
For the purpose of this study, we designed and optimized a custom target-enrichment assay 
based on in-solution hybridization, targeting relevant genes involved in human DCM being 
summarized in Supplementary material online, Table S1. The custom target region encompasses 
all known coding exons of each gene. In total, we analysed 639 patients with known DCM 
diagnosed according to current ESC guidelines. Importantly, all 639 samples from the eight 
countries analysed in this study were processed according to the same standard operating 
procedures (SOPs) and quality control measures, allowing detailed inter-sample comparisons. 
Figure 1 details the origin of patients and the workflow applied. As shown in Table 1, the 
proportional number of patients with familial DCM was 49%. Left ventricular ejection fraction, 
indicating disease severity, was 31.2% (±12.1), while the NYHA functional class, being a measure 
of the individual clinical status, was mainly in I–III. Heart transplantation was performed in 113 
patients and another 130 received ICD implantation. Gender distribution was as expected with 
more male patients being affected. For detailed patient characteristics, please refer to Table 1.  
Table 1. Patient characteristics 
Characteristics  DCM patients (n = 639)  
 
Gender (%)  
 Woman  212 (34)  
 Man  405 (66)  
Family history familial DCM (%)  
 Sporadic  271 (51)  
 Familial  265 (49)  
LVEF (%)  31.2 ± 12.1  
LVEDD (mm)  64.4 ± 11.2  
NYHA functional class (%)  
 I  145 (28)  
 II  164 (32)  
 III  165 (32)  
 IV  39 (8)  
Received heart transplantation (%)  
 No  465 (80)  
 Yes  113 (20)  
Received ICD implantation (%)  
 No  344 (73)  
 Yes  130 (27)  
  
 
As a pre-requisite for clinically applicable tests, we reached a very high 50-fold target coverage 
of 99.1% over all genes by iteratively improving the enrichment assay in a preceding 
establishment phase, being relevant to conclude positive as well as negative test results in 
individual patients. The mean coverage over all DCM genes was as high as 2526-fold (Figure 2A). 
To determine the accuracy, specificity, and sensitivity of the proposed diagnostic tool, we 
followed-up 25 randomly selected amplicons containing at least one variant by Sanger sequencing. 
From 5909 readable bases in the Sanger sequencing, we observed 5879 true-negative calls (TN) 
and 26 true-positive (TP) calls. Only three false-positive (FP) calls and one false-negative (FN) 
call were found, together resulting in a sensitivity [TP/(TP + FN)] of 96.3% and specificity 
[TN/(TN + FP)] of 100% and accuracy [(TP + TN)/(TP + FP + FN + TN)] of 99.9%. To further 
increase the depth of variants for benchmarking, we enriched and sequenced the well-genotyped 
HapMap sample NA12878 using the same methodology. When testing the standard GATK cut-off 
values, we find a sensitivity of 100% and an accuracy of 85.4%. Using our filter off-sets described 
in materials and methods, we achieved a much higher accuracy of 91.3% by maintaining a 
sensitivity of 99.0%. After manual inspection of the false-positives that could not be validated by 
Sanger, we postulated that at least some of these must be true variants. Hence, we exemplarily 
subcloned genomic DNA of patients with a variant call in the NGS data set and negative Sanger 
sequencing and sequenced individual clones. As shown in Supplementary material online, Figure 
S3, wild-type as well as mutant clones from one individual can be found, which is not obvious in 
the Sanger sequence, indicating that the actual accuracy of NGS is even higher than the estimated 
and that Sanger sequencing may miss at least some of the variants. 
 
 
 
Figure 2. Sequence coverage and variant distribution per Gene. (A) Graph representing the sequence coverage of dilated 
cardiomyopathy genes. Vertical axis is showing the target coverage for every gene, colour codes give the read depth of 
coverage. The horizontal axis is giving the mean coverage in reads per gene (pale green line). Over all dilated 
cardiomyopathy genes a mean coverage of 2526 could be found. (B) Bar graph demonstrating the distribution of identified 
known disease causing mutations (category Ia) in the whole patient cohort over all tested dilated cardiomyopathy genes. 
Colour code is giving information on the different CMP subtypes as annotated in HGMD. Dilated cardiomyopathy 
mutations are painted in petrol, hypertrophic cardiomyopathy, ARVC, LongQT, and Brudgada mutations are coloured in 
blue, ranging from dark to pale.  
Distribution of mutations in dilated cardiomyopathy patients 
In total, we identified 8269 unique genetic variants, adding up to 359 669 variants in the 639 
patients across the investigated target region. On average, each patient carries 563 variants in this 
region. To gain information on the relevance of each variant, we performed a stepped filtering 
approach, first by eliminating known common variants. We thereafter annotated the remaining 
variants using ANNOVAR, snpEff, Genometrax (Biobase), and SNPs&GO. 
 
We then applied the classification presented in Figure 1C. A known cardiomyopathy mutation 
(category Ia; reported in HGMD as cardiomyopathy or channelopathy variant) was found in 305 
patients (48% of all patients). When we additionally excluded variants observed in a large non-
DCM control cohort (ESP whole exome sequencing project
8
) (=category Ib), we still find in 294 
patients (46%) a known mutation previously reported as disease causing. Figure 2B gives an 
overview over the distribution of mutations across the screened DCM genes. When considering 
only DCM-causing mutations by excluding mutations of other cardiomyopathies, a known 
mutation is found in 101 patients (16% of all patients). 
 
Since many cardiomyopathy cases will be caused by rare or private mutations, which are not 
yet annotated in databases such as HGMD, we next searched in all patients for ‘likely’ disease 
mutations (category II). The ‘likely’ mutations include frameshift insertions/deletions, stop-gain/-
loss variants, and splice-site mutations within the target genes. In addition to the category Ia 
variants, our analysis yielded insertions with resulting frameshifts in three different genes across 
13 patients and frameshift deletions in 10 DCM genes covering a total of 37 patients. We also 
identified 11 individual splicing variants in 8 DCM genes in a total of 37 patients and 60 stop-
gain/-loss variants in 17 genes in another 67 patients. Altogether, we find 117 previously not 
annotated highly ‘likely’ pathogenic variants in 26 genes for 147 patients (23%). 
 
To search for ‘potential’ disease mutations (category III), we selected all non-common, non-
synonymous variants, and applied bioinformatics methods to predict a detrimental effect of each 
variant on the protein function. By using SNPs&GO, we classified as many as 939 variants as 
neutral and 141 unique variants as potentially disease causing. These 141 variants were detected in 
221 patients and are rare judged by their frequency. Figures 3 and 4 exemplify the distribution of 
variants for representative disease genes (Nexilin, Titin, Lamin A/C). See also Supplementary 
material online, Figure S1 for the whole list of genes. To investigate whether the variants from 
category II–III indeed represent rare mutations, we calculated the percentage of Singletons, which 
means variants found uniquely in only one patient. Here, the rate was 21.8% in the categories II–
III, compared with 1.6% in the removed variants, underlining the stringency of the classification 
approach.  
  
 
 
 
Figure 3. Variant distribution in NEXN. The high coverage of each gene, exemplified for the nexilin gene, enables a 
reliable read mapping, variant calling and subsequent filtering of genetic variants. The black boxes below the coverage plot 
are representing the targeted region of the NEXN gene. Sequence alignments show the variants and their chromosomal 
location. The scheme at the bottom of the figure gives an overview on the variant classification. In total, seven different 
non-synonymous variants and one stop mutation in two patients and one non-frameshift variant in one patient were found 
in NEXN. Numbers in brackets are the total sum of variants found in the cohort. Predicted benign = green; deleterious = 
red. 
  
 
 
 
Figure 4. Variant classification in TTN and LMNA. Diagrams are showing the number of individual variants of different 
types for (A) titin and (B) lamin. Numbers in brackets are the total sum of variants found in the cohort. HGMD disease 
variants (category Ia) were annotated using the Biobase Human Genome Mutation Database, regardless of their appearance 
in dbSNP137common. All subcategories (non-synonymous, frameshift, stop/start, predicted disease, predicted benign, 
splicing, synonymous) were annotated after removing those common variants. For prediction of non-synonymous variants, 
SNPs&Go was used. Colours of the boxes indicate a potential benign (green) or deleterious (red) effect. Variant 
categorization is indicated below the deleterious variant types. Sketch below the diagram is showing the target region of the 
gene (black) and the distribution of common (green) and known and likely/potential pathogenic variants (red). 
  
Looking at the total number of variants within the DCM genes, the majority of variants (13%) 
can be found in the titin gene (TTN) (Figure 5A). This is not surprising since TTN is the largest 
human gene and accounts for >20% of the total target region. When normalizing, the number of 
variants to the size of each gene (Figure 5B), a rather even distribution can be found, disproving 
the existence of instability hotspots in DCM genes. A detailed view on the distribution of all likely 
and potentially pathogenic variants is given in Figure 5C showing the number of splice, 
frameshift, stop, non-synonymous, and predicted disease causing (SNPs&GO) non-synonymous 
variants. 
 
 
 
Figure 5. Variant distribution in dilated cardiomyopathy genes. Pie charts representing the total number of variants per 
dilated cardiomyopathy genes (A) and after normalization to the gene size (B). (C) Blue bar graphs are showing the total 
number of variants over all patients by predicted effect type for each gene (splice, frameshift, stop, non-synonymous, and 
predicted disease). Curly bracket is grouping the likely truncating variants (category II) and indicates the potential disease 
causing variants (category III).  
Distribution of the functional effects of dilated cardiomyopathy mutations 
Numerous studies suggest different phenotypic manifestations or severities depending on the 
gene affected, type and number of mutations. Hence, we tested if DCM patients in our cohort 
might carry multiple disease mutations, e.g. compound mutations (category Ib–III). Strikingly, 
such compound heterozygous states were found in 49 (7%) patients and combined heterozygous 
mutations were found in 243 patients (38%). Remarkably, we detected in 82 patients (12.8%) at 
least 3 mutations (Table 2). Considering only the very stringent category Ib variants of annotated 
disease mutations after exclusion of variants detected in additional control cohorts, still 82 patients 
(12.8%) carry at least 2 known disease mutations. As expected, using logistic regression, we find a 
significant association of patients having a disease mutation and familial DCM (P = 0.03, category 
Ib–III) (Table 3). To test if those results are driven by an effect of the large ttn gene, we repeated 
the analysis after exclusion of any ttn variant and still find 79 patients (12.4%) with at least two 
category Ib variants (Supplementary material online, Table S5).  
Table 2. Multiple mutations affecting single patients 
Number of  
mutations  
HGMDa variant  
pos patients (%)  
Category Ib–IIIb  
variant pos patients (%)  
   
0  345 (54.0)  171 (26.7)  
≥1  294 (46.0)  468 (73.2)  
≥2  82 (12.8)  243 (38.0)  
≥3  14 (2.2)  82 (12.8)  
≥4  2 (0.3)  16 (2.5)  
   
 
 
a Category Ib. 
b Either category Ib or category II or category III. 
Table 3. Association of familial and sporadic dilated cardiomyopathy with number of mutation positive results 
  No. of patients  
No. of patients having  
category Ib–IIIa variant  
P-value from  
logistic regression  
OR (95% CI)  
     
Sporadic DCM  271  185  0.03  Reference  
Familial DCM  265  203    1.52 (1.04–2.23)  
     
 
a Either category Ib or category II or category III. 
OR, odds ratio; CI, confidence interval. 
 
When looking more closely at the variants annotated using the HGMD database (CatIb), a 
large portion of disease causing mutations are known to cause arrhythmogenic right ventricular 
cardiomyopathy (ARVC) (31%), HCM (16%), or channelopathies (6%) (Figure 6A), indicating a 
marked overlap not only related to disease genes, but also to specific mutations in 
cardiomyopathies. Hence, based on current literature, all genes investigated in this study were 
classified according to the different cell components or functions they contribute to 
(Supplementary material online, Table S1).
9
 Next, we summed up the number of patients carrying 
a category Ib mutation in the different groups. Figure 6B details the groups and the identified 
number of patients. Based on this classification, the sarcomere group shows the highest number of 
patients having a mutation (14%), followed by ion flux (13%), z-disc/cytoskeleton (12%), and 
intercalated disc (11%).  
 
 
 
Figure 6. Variant distribution and classification by cell components. (A) Variants were annotated using HGMD and filtered 
by Exome Sequencing Project variants (category Ib). Within all annotated mutations, we find the highest number described 
to cause dilated cardiomyopathy (35%), ARVC (31%) and hypertrophic cardiomyopathy (16%). Also, a substantial number 
is found for Long QT and Brugada syndrome (left pie chart). The right pie chart is giving percentages of affected patients 
in relation to dilated cardiomyopathy-cohort size (n = 639). B) Genes were grouped based on their contribution to different 
cellular compartments or functions in six groups (ion flux, nucleus, cell membrane, sarcomere, z-disc/cytoskeleton or 
intercalated disc). Given are the number (percentage) of patients carrying a category Ib disease mutation. Patients having a 
variant in more than one group were counted multiple times. 
  
We next asked whether we might identify specific genotype–phenotype associations in this 
large cohort. This would have direct clinical implications, since a genotype-guided risk assessment 
could improve patient selection for intensified monitoring or directed therapies. First, we 
investigated the gene groups introduced above and the available phenotypes. In an exploratory 
association analysis by using a stepwise forward selection, we could identify a logistic regression 
model for the group ‘nucleus’ being a significant predictor for ICD-carrier status in DCM 
(unadjusted P = 0.02). The odds ratio (OR) for patients carrying such variants was 2.44 [95% 
confidence interval (95% CI): 1.13–5.28]. This association was mainly driven by the nuclear gene 
RBM20, having an OR of 5.65 (1.89–16.86; P = 0.002). For the age at diagnosis, which might be 
relevant for establishing genetic testing in relatives, we find a significant association between 
MYH6 and ADRB3 mutations (Tables 4 and 5). Other clinically relevant associations were found 
for SMYD1, which we here suggest as novel disease gene for DCM, as well as for alpha-crystalin 
B (CRYAB) mutations, both were associated with LVEF. Alterations in left-ventricular diameter 
(LVEDD) could be seen in association with TBX20 (OR: 0.45, 0.22–0.94; P = 0.03). Since a 
significant number of patients also received heart transplantation (HTX) due to end-stage heart 
failure (20% of the cohort), we investigated associations with HTX. Here, we found a significant 
association with MYPN having an OR of 4.23 (1.04–17.18). 
Table 4. Association between genotypes and dilated cardiomyopathy 
Gene  Phenotype  
No. of  
patients  
Patients with  
category Ib-IIIa  
variants  
P-value from  
logistic regression  
OR (95% CI)  
      
CRYAB  LVEF  582  2  0.04  0.05 (0.00–0.81)  
MYPN  
Received 
HTX  
        
 No  465  4    Reference  
 Yes  113  4  0.04  4.23 (1.04–17.18)  
RBM20  
Received 
ICD  
        
 No  344  5  0.002  Reference  
 Yes  130  10    5.65 (1.89–16.86)  
SMYD1  LVEF  582  2  0.03  4.42 (1.14–17.10)  
TBX20  LVEDD  538  7  0.03  0.45 (0.22–0.94)  
MYH6  
Age at 
diagnosis  
439  8  0.03  0.63 (0.41–0.96)  
ADRB3      2  0.04  0.36 (0.14–0.94)  
      
 
Only significant associations are shown (unadjusted α = 5%, two-sided). 
a Either category Ib or category II or category III. 
OR, odds ratio; CI, confidence interval. For LVEF OR are calculated per 10% step. For LVEDD OR are calculated per 10 
mm step. For age at diagnosis, OR are calculated per 10 years step. 
  
Table 5. Mutation counts by country 
Country  No. of patients  
No. of category  
Ib-IIIa variants  
P-value from  
poisson regression  
RR (95% CI)  
     
Denmark  100  130  0.04  Reference  
England  70  106    1.16 (0.90–1.51)  
France  92  111    0.93 (0.72–1.20)  
Germany  98  93    0.73 (0.56–0.95)  
Italy  78  97    0.96 (0.74–1.24)  
Netherlands  70  99    1.09 (0.84–1.41)  
Spain  82  107    1.00 (0.78–1.30)  
Sweden  49  71    1.11 (0.83–1.49) 
     
 
a Either category Ib or category II or category III. 
RR, relative risk; CI, confidence interval. 
 
Differences of dilated cardiomyopathy mutations across Europe 
This study includes a total of 639 patients from eight countries, enabling us to investigate the 
geographical distribution of cardiomyopathy relevant variants. When considering genetic variants 
from category Ib–III (Supplementary material online, Table S6), we observe small yet statistically 
significant differences between countries regarding the rate of mutations (variants per patient), 
with Germany showing the lowest rate of 0.98 and Great Britain showing the highest rate of 1.51 
(global P = 0.04, Poisson regression). The rate of mutation positive patients for single genes and 
across countries is depicted in Figure 7. For example, the rate of patients carrying a TTN variant 
ranged from 0.56 in Dutch patients to 0.20 in German patients (global P < 0.001, logistic 
regression). However, mutation frequencies of DCM genes are clearly more homogeneous than 
previously reported in smaller studies, suggesting that genetic testing for DCM can be applied in a 
uniform setting across Europe.  
 
 
 
 
Figure 7. Country-specific rates of mutation positive patients by dilated cardiomyopathy genes. The rates of patients 
carrying at least one category Ib–III variant per gene are represented by coloured dots, 95% Clopper–Pearson confidence 
interval are indicated by coloured lines. Countries without mutations in a certain gene are not plotted. 
  
Discussion 
To our knowledge, this is the most comprehensive study on the contribution of DCM-causing 
genes to date. The data reported shed light on the distribution of genes, the number of mutations 
and mutational burden of patients with DCM. 
 
Next-generation sequencing technologies (NGS) have emerged as a fast alternative to Sanger-
sequencing, providing the analytical characteristics for the comprehensive exploration of genetic 
mechanisms.
10
 However, NGS retains some weaknesses, such as the incomplete representation and 
coverage of exons, bearing the risk of limited sensitivity and detection failure of clinically relevant 
mutations. The use of target enrichment followed by NGS, for high-throughput genetic testing of 
disease genes for DCM, HCM and other cardiomyopathies has now become feasible and 
technically validated as shown by the nearly complete coverage and high accuracy of the approach 
described here. 
 
To reduce the number of likely and potentially pathogenic variants, bioinformatics analyses 
must include a filter step, e.g. excluding common variants present in databases like dbSNP. 
However, it is known that dbSNP is ‘contaminated’ with a small but yet substantial number of 
pathogenic alleles.
11
 On the other hand, disease mutation databases contain potentially benign 
variants, previously classified as disease causing. Therefore, to substantiate the disease causing 
nature of a variant, further investigations must include a screening of well-phenotyped control 
cohorts from diverse populations and a detailed follow-up on the clinical circumstances in each 
patient and family, for example, by co-segregation analyses. But since families are often small and 
many patients are classified as sporadic, the ultimate solution of this intricate problem seems 
illusive. Mestroni and Taylor
12
 recently reviewed how the progress in genetic research already 
changed the view on the genetic basis of DCM. It is hence obvious that bioinformatics strategies 
must grow together with the enormous amount of data from adequately sized and high-quality 
NGS studies. With regard to a functional prediction, Thusberg et al.
13
 observed significant 
differences between algorithms, but found that algorithms such as the here applied SNPs&GO 
perform already surprisingly well. However, at least by now, proving new variants or genes as 
disease causing requires further efforts to validate them through functional and familial studies and 
large-scale population-based control cohorts sequenced by NGS. 
 
Previous publications have given rise to the notion that disease-causing gene mutations may 
underlie geographical disparities.
14
 In our study, we enrolled patients from eight countries to create 
a European map of cardiomyopathy relevant variants and find only modest differences across the 
countries. We observed the lowest number of variants in the German cohort when compared with 
the other countries. This effect may be due to a higher number of patients in Germany bearing 
sporadic forms of DCM. However, differences caught our attention for Sweden, where we 
detected the most category Ib–III variants in DSP and MYBPC3 compared with the other 
countries, as well as for the Netherlands, where we observed the highest number in TTN variants. 
With respect to PLN, we only uncovered one single mutation in our study population, suggesting 
that the previously mentioned mutation frequencies might express a very local phenomenon rather 
than a common cause of DCM. The overall distribution of mutations in DCM disease genes all 
over the participating countries appeared to be more homogeneous than expected. 
 
In clinical routine, only detailed workup of cases and their families allows to uncover familial 
aggregation.
15
 Often this is impeded by small family structures, unavailable family members or 
incomplete penetrance, which classifies many cases as sporadic or idiopathic. However, this does 
not exclude a genetic cause of DCM in this individual patient. By introducing familial and 
sporadic DCM cases in our study, we were able to compare both groups in a comprehensive and 
well-controlled manner. By doing so, we observed significantly higher mutation rates in familial 
cases than in the sporadic ones (OR: 1.52). However, as shown, we find also in many cases of 
idiopathic DCM a known and well-characterized disease mutation. Hence, the current work 
underlines that even if a definite familial DCM may not be proven, a genetic aetiology cannot be 
ruled out. The decision to genetically test sporadic cases should be, however, taken carefully to 
avoid unnecessary costs and inconclusive results. By limiting testing to familial DCM and risk 
groups of idiopathic DCM, e.g. with documented arrhythmias, would be an apparent conclusion. 
  
Genotype–phenotype correlations will be of increasing importance to predict the clinical 
manifestations of genetically diagnosed patients. However, there are few existing studies on 
genotype–phenotype correlations in selected cohorts. Convincing data exist for the clinical impact 
of LMNA. Here, several studies have repeatedly shown a poor prognosis for LMNA mutation 
carriers due to the occurrence of ventricular arrhythmias and sudden cardiac death.
16
 Similarly, it 
was shown that RBM20 mutation carriers with DCM present with a fast progression of heart 
failure and high risk for arrhythmias.
17
 In our study, the often-maligned stop or frameshift 
mutations in LMNA ranked within the top three genes of our tested gene panel and we find LMNA 
to having together with RBM20 the most category Ib–III mutations for genes with a comparable 
size. While we observed a significant association of ICD-carriers with the functional gene group 
‘nucleus’ to which LMNA belongs, a statistically significant effect could only be seen for RBM20, 
where we find an association with the ICD-carrier status. It should be kept in mind that present 
results rely on a small number of observations for some strata and that probability values are not 
corrected for multiplicity. When using an exact test, the probability value MYPN and HTX (P = 
0.04) decreases to P = 0.0051, while the probability value for CRYAB (P = 0.04) decreases to P = 
0.02 and RBM20 (P = 0.002) remains unchanged. While for RBM20 our results may be seen as 
validation of previous findings and hence underline the importance for testing this gene now 
routinely, the newly found associations require additional replication in independent cohorts of 
DCM patients. 
 
Remarkably, we find in our DCM cohort a high percentage of mutations previously described 
for HCM, ARVC, or channelopathies, which questions the hypothesis of the allelic nature of 
cardiomyopathies. For instance, we found plakophilin-2 to be the most frequently affected gene 
when considering only known pathogenic mutations. Plakophilin-2 mutations represent a frequent 
cause of ARVC, which is characterized by the degeneration of cardiomyocytes and resulting 
arrhythmias.
18
 A similar finding was recently provided by Pugh et al.,
19
 underlining that our 
findings are not spurious. While they hypothesized that misdiagnosis in their broad referral 
population of an ordering provider could be one potential explanation, we nearly can exclude this 
due to the controlled setting of our study. To avoid phenotypic misclassification, we relied on 
experienced clinicians for recruiting to our best knowledge only DCM patients and performed 
additional phenotyping by coronary angiography, cMRI, or myocardial biopsy where appropriate. 
We rather hypothesize a pathophysiological link between conductance defects and resulting 
cardiac mechanical disparities. However, even then a certain overlap of phenotypes will explain at 
least a part of these findings. 
 
We were to our knowledge first to introduce genetic testing of cardiomyopathy patients for the 
large TTN gene using NGS.
3
 In accordance with recent findings by Herman et al.
20
 reporting TTN 
truncating mutations to be the cause of DCM in ∼25% of familial and in 18% of sporadic cases, 
we were able to identify such mutations in 19% of familial and 11% of sporadic cases. 
Interestingly, 44% of all patients with a truncating TTN variant also had additional known disease-
causing variants in at least one other gene, suggesting that in these cases, the TTN variant may not 
be the sole cause of DCM, underlining the importance to investigate a broad gene panel rather than 
selected genes.
19
 In this regard, this study sheds for the first time light on the role of TTN and other 
mutations to DCM in a considerable high number of patients. This is also underlined by the high 
clinical sensitivity of our approach of 46% (considering only known mutations, cat Ib) up to 
73.2% (considering cat Ib–III), which is already in the range of the sensitivity reported for HCM.21 
This is in contrast to previous studies that reported lower sensitivity values, maybe due to more 
inhomogeneous cohorts or the use of NGS in subgroups of patients.
19
 This maybe also the reason 
why MYBPC3 mutations, which we surprisingly find very frequently, could not be associated with 
DCM in some previous studies and hence was long debated if it contributes to DCM at all. For the 
group of patients without Ib–III variants (26.7%), family-based whole exome sequencing or 
alternative approaches should be applied to identify possible genetic defects in so far unknown 
disease genes, with BAG3 being one recent example.
22,23 
 
Even if genetic investigations do not resolve a familial disease, other mechanisms such as 
epigenetic modifications (microRNAs, Histon-modifications, DNA methylation) should be taken 
into account.
10,24
 Only very recently, first studies underlined the role of DNA methylation on heart 
failure and DCM.
25,26
 While the studies did not provide evidence for the causality or inheritance of 
the observed changes, it will be interesting to investigate the shown proof-of-principle in pedigrees 
with DCM. Furthermore, the increasing numbers of genetic susceptibility loci harbouring common 
polymorphisms add to the concept that DCM is a complex disorder, with rare and common genetic 
variants and environmental factors driving disease onset and outcome. 
 
With improved accuracy, efficiency, and decreasing cost, NGS is becoming the sole standard 
for gene sequencing. It must be noted that high analytical standards must be the basis for 
introducing such methodology for the diagnostics of DCM. We were able to show high-analytical 
fidelity and consistency in a large patient cohort, demonstrating that targeted NGS is already well 
suited to be applied in clinical routine diagnostics, substantiating the ongoing paradigm shift from 
low- to high-throughput genomics in medicine. However, many third party providers do not 
publish quality indices that should be pre-requisite for introducing their technologies into the 
clinics. Our study hopefully stimulates not only the single physician to demand for transparency in 
regard to quality but also helps to impact on future recommendations for the next-generation of 
genetic testing. By means of our atlas of the genetics of human DCM, we aspire cardiologist and 
human geneticists to soon be able to apply our findings to the individual patient with 
cardiomyopathy in daily clinical practice. 
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